US equities
|
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
NVDA
$215.38
▼-1.17%
GOOGL
$324.89
▲+1.34%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
MSFT
$531.01
▼-0.06%
SNDK
$1,404.77
▲+7.66%
MU
$983.23
▲+5.86%
META
$612.49
▼-1.24%
NVDA
$215.38
▼-1.17%
GOOGL
$324.89
▲+1.34%
TSLA
$404.22
▼-0.80%
SPCX
$145.23
▼-2.25%
MSFT
$531.01
▼-0.06%
SNDK
$1,404.77
▲+7.66%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Silo Pharma, Inc. - Common Stock
(NQ:
SILO
)
1.340
+0.050 (+3.88%)
Delayed Quote
Updated: 3:49 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silo Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Why MongoDB Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
↗
June 05, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 04, 2025
Via
Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
↗
June 04, 2025
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket
↗
May 27, 2025
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with Nasal Spray Device Study for SPC-15
May 21, 2025
Via
Investor Brand Network
Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15
May 21, 2025
Study is expected to deliver final device data and documentation needed for planned FDA IND submission
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes $2 Million Public Offering of Shares and Warrants
May 19, 2025
Via
Investor Brand Network
Silo Pharma Announces Closing of $2 Million Public Offering
May 16, 2025
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Prices $2 Million Public Offering of Common Stock and Warrants
May 16, 2025
Via
Investor Brand Network
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
May 15, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 15, 2025
Via
Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
↗
May 15, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via
Chartmill
These stocks are gapping in today's session
↗
May 15, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
InvestorkNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
May 15, 2025
Via
Investor Brand Network
Silo Pharma Announces Pricing of $2 Million Public Offering
May 15, 2025
From
Silo Pharma, Inc.
Via
GlobeNewswire
Silo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD Treatment
↗
May 14, 2025
The company announced FDA-requested toxicology studies for its PTSD treatment SPC-15, fueling optimism for a 2025 IND submission and Phase 1 trial.
Via
Stocktwits
Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15
May 14, 2025
From
Silo Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
May 14, 2025
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
May 14, 2025
Via
Investor Brand Network
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
May 14, 2025
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar Market
From
Silo Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
May 01, 2025
Via
Benzinga
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant
April 30, 2025
Via
Investor Brand Network
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study
April 30, 2025
From
Silo Pharma, Inc.
Via
GlobeNewswire
EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models
↗
April 30, 2025
Silo Pharma reported positive preclinical results for its ketamine-based implant SP-26, designed to treat chronic pain and fibromyalgia.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 28, 2025
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
April 28, 2025
Via
Investor Brand Network
Topics
Intellectual Property
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
April 28, 2025
From
Silo Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
March 26, 2025
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
March 26, 2025
Via
Investor Brand Network
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
March 26, 2025
From
Silo Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
